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Abstract
Analyzing the mutational load of driver mutations in melanoma could provide valuable infor-
mation regarding its progression. We aimed at analyzing the heterogeneity of mutational
load of BRAF V600E in biopsies of melanoma patients of different stages, and investigating
its potential as a prognosis factor. Mutational load of BRAF V600E was analyzed by digital
PCR in 78 biopsies of melanoma patients of different stages and 10 nevi. The BRAF V600E
load was compared among biopsies of different stages. Results showed a great variability in
the load of V600E (0%-81%). Interestingly, we observed a significant difference in the load
of V600E between the early and late melanoma stages, in the sense of an inverse correla-
tion between BRAF V600E mutational load and melanoma progression. In addition, a
machine learning approach showed that the mutational load of BRAF V600E could be a
good predictor of metastasis in stage II patients. Our results suggest that BRAF V600E is a
promising biomarker of prognosis in stage II patients.
Introduction
BRAF mutations are considered to be one of the earliest events in melanoma development [1].
The most common somatic mutation in BRAF is a V600E, accounting for 70% to 88% of all
BRAF mutations [2]. V600E mutation is clinically relevant, because based on its presence,
many patients receive targeted therapy, although paradoxically, BRAF V600E has been
reported to be more frequent in benign (�80%) than in dysplastic nevi (�60%) or melanoma
(�40%-45%) [3, 4]. Thus, the detection of the BRAF V600E mutation in melanoma samples
is used to select patients who should respond to BRAF inhibitors (like vemurafenib or
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dabrafenib), although unfortunately, most metastatic patients with initial tumor response
develop resistance [5].
Different techniques are routinely used to determine BRAF status in clinical samples, the
most widely used being the Cobas1 4800 BRAF V600 Mutation Test (Roche Molecular Diag-
nostics), based on a polymerase chain reaction (PCR). However, this test determines qualita-
tively the presence or absence of the mutation. In this sense, tumor heterogeneity can affect the
sensitivity for somatic mutation detection, which may lead to false negatives [6].
Actually, malignant melanoma is a highly heterogeneous neoplasm, composed of subpopu-
lations of tumor cells with distinct phenotypes [7], in which different subpopulations of the
tumor may have different behavior and different response to treatments. In this sense, previ-
ous studies have reported that a high mutational load of BRAF V600E is associated with a bet-
ter response to BRAF V600E inhibitors in stage III and IV patients [8].
Based on this evidence, it seems clear that a quantitative assessment of mutations would be
more reliable and useful than a qualitative assessment. In this regard, digital PCR (dPCR) is an
analytical technique for absolute quantitation of nucleic acid samples based on PCR amplifica-
tion of single template molecules. dPCR works by partitioning a sample of DNA into thou-
sands of individual, parallel PCRs. Following PCR analysis, the fraction of negative reactions is
used to generate an absolute count of the number of target molecules in the sample, without
the need for standards or endogenous controls. This method provides thus a sensitive and pre-
cise quantification of the load of particular mutations in tumor samples.
Therefore, we aimed at analyzing the heterogeneity in the mutational load of BRAF V600E
in biopsies of melanoma patients of different stages at diagnosis, in order to investigate if the
mutational load of BRAF V600E could serve as a useful prognosis factor.
Materials & methods
Ethics statement
The study protocol conformed to the tenets of the Declaration of Helsinki (Version Brazil
2013) and was approved by the Euskadi Ethics Committee (PI+CES BIOEF 2016–06). All
patients (including those with nevi) gave written informed consent to participate in the study
and to use their biopsies as material for research.
Patients and samples
The study focused on 78 patients, all of them with histologically confirmed malignant mela-
noma: 41 women and 37 men; mean age 61 years (range 24–85: see Table 1). Patients were
untreated, other than primary surgery. Disease stages were classified according to the AJCC
(American Joint Committee on Cancer). A group of 10 nevi was also included in the study.
The melanoma patients at stage II were divided into two groups according to disease prog-
nosis: patients with good prognosis (without metastasis in the time considered, median follow-
up of 4 years) and metastatic patients (patients who developed metastasis after surgery,
median, 1.4 years). Of the 38 stage II patients, 21 (55.26%) developed metastasis during follow-
up.
Immunohistochemistry (IHC)
The formalin fixed paraffin embedded (FFPE) biopsy sections (3 μm thick) were placed on
3-aminopropyletxylene-covered slides. Subsequently, sections were stained with mouse mono-
clonal antibody against BRAF V600E (1/100 dilution; clone VE1) following the Ventana Medi-
cal Systems’ protocol and as previously described [9]. Briefly, staining was performed on a
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Ventana BenchMark Ultra (Ventana Medical Systems, Inc., Tucson, AZ, USA). The staining
protocol included the use of Cell Conditioning 1 for 64 minutes; pre-peroxidase inhibition
with 3% hydrogen peroxide for 10 minutes at 37˚C and primary antibody incubation for 70
minutes. Amplification kit was applied for 4 minutes at 37˚C to increase the signal intensity.
The OptiView DAB IHC Detection kit was used to detect BRAF V600E protein expression.
Tissues were counterstained with hematoxylin for 16 minutes and Bluing Reagent for 4 min-
utes. Then, stained sections were scanned by NanoZoomer S210 Digital slide scanner (Hama-
matsu Photonics, Japan). The scoring of VE1 antibody staining was performed by visual
inspection of two independent researchers. The scores range from 0 to 3 (0 for negative stain-
ing and 1–3 for different levels of positive staining).
Digital PCR (dPCR)
DNA was isolated from 78 paraffin-embedded skin biopsies from different melanoma stages,
as well as from 10 nevi, using HigherPurityTM FFPE DNA Isolation Kit (Canvax Biotech). To
detect and quantify the V600E mutation, digital PCR was performed with QuantStudio 3D
Digital PCR System (Applied Biosystems), in combination with Taqman dPCR Liquid Biopsy
Table 1. Clinical characteristics of melanoma patients (n = 78).
N
Sex
Women 41
Men 37
Age at diagnosis Range 24–85
AJCC Stage at diagnosis
In situ 3
IA 7
IB 17
IIA 14
IIB 12
IIC 12
IIIA 2
IIIB 5
IIIC 2
IV 4
Disease evolution
Disease free 43
Metastasis 35
Localization
Head and Neck 14
Trunk 25
Upper extremity 6
Lower extremity 24
Hands and foot 6
Others 3
Breslow Thickness (mm)
<1 17
1–4 35
>4 26
https://doi.org/10.1371/journal.pone.0230136.t001
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Assays (Hs000000004_rm and Hs000000003_rm). An evaluation of the technique was done on
10 commercial melanoma cell lines (S1 Table).
Data analysis was performed with the AnalysisSuite Software v3.1.4 (Applied Biosystems).
Tumoral areas were measured using ImageJ software in stained hematoxylin-eosin scanned
images. The areas occupied by stroma cells were excluded and the rate of melanocytes or mela-
noma area with respect to total area of the biopsy was applied to correct mutational load (S2
Text and S1 Fig).
QuantStudio 3D Digital PCR System was also used to determine the copy number of BRAF
in some samples with BRAF V600E mutational load higher than 60%. We used the BRAF Taq-
Man Copy Number Assay (Hs04935060_cn) and TERT TaqMan™ Copy Number Reference
Assay as a reference. Genomic copy number of BRAF was determined as the ratio between
BRAF and TERT, multiplied by 2:
BRAF copies=ul
RNaseP copies=ul x 2.
Statistical analysis and classification
Fisher’s exact test and Mann–Whitney U-test were used to determine the level of statistical sig-
nificance between groups by means of the SPSS statistical software. Concordance between
dPCR and IHC results was determined by Spearman’s ρ test.
Initial predictive modelling based on logistic regression, was performed using the ’caret’
package for R. Then, a more standardized machine learning analysis was performed using ’sci-
kit -learn’. We applied a machine learning Decision Tree classifier, with a Leave-One-Out
cross-validation test to separate a metastatic response from a non-metastatic response.
For a power analysis of the effect size, we calculated the Cohen’s effect size.
Results and discussion
We have analyzed the mutational load of BRAF V600E in 78 paraffin-embedded skin biopsies
from different melanoma stages, based on AJCC classification, as well as from 10 nevi. Quant-
Studio 3D Digital PCR System was used in combination with Taqman technology to detect
and quantify the BRAF V600E mutation. To remove the confounding contribution of sur-
rounding, healthy tissue, the BRAF V600E mutational load corresponding to the tumor tissue
was obtained by correcting the obtained value by the proportion of tumor area in each biopsy
based on immunohistochemistry (IHC) images obtained with the BRAF V600E antibody VE1
(Fig 1) (see Material and Methods).
Results show a great variability in the biopsies regarding their BRAF V600E mutational
load, ranging from 0% to 81% (median 1.27%). Initially, we expected only values of mutational
load between 0 and 50%, based on the assumption that the V600E mutation would be the
result of a single, mutational event (i.e. only one mutant chromosome per diploid cell). To test
whether the values of V600E mutational load> = 60% were the result of amplification, as sug-
gested by Willmore-Payne et al. [10], we analyzed the copy number of BRAF in those 3 sam-
ples, all of which showed 3 or 4 copies of BRAF. Therefore our results confirm that in those
samples with load of V600E> = 60% this is due to an amplification of BRAF.
Initially, the concordance between dPCR and IHC was relatively high, and significant
(Spearman’s ρ = 0.652, p<0.01). The value of Spearman’s ρ can be explained by a few samples,
which did not perfectly match: 17 samples were classified as negative by IHC and positive by
dPCR. This discordance could be due to the higher precision of dPCR, as it is able to quantify
rare mutants at a load of�0.1%. On the other hand, there were 4 samples which were clearly
positive with IHC but negative or with low mutational load with dPCR. This discrepancy can
be explained as the result of synonymous codons for V600E [11, 12]. To test if the 4 discrepant
samples described above contained the V600E2 mutation (c.1799_1800TG>AA) instead of
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the canonical c.1799T>A, we performed dPCR with Taqman probes targeting c.1799_
1800TG>AA. The results showed that all of the four samples had that mutation, one of them
in a high percentage (about 50%). Based on these results, we also analyzed this mutation in the
rest of the samples that had been classified as negative with the assay for c.1799T>A. Many of
them presented the mutation, but the load was < 5% in all the cases (Fig 1). This was in accor-
dance with other studies that show that the most common mutation is c.1799T>A [12].
Besides, we decided to analyze the mutational load of V600E in 10 nevi, because it is
described that a great percentage of nevi present that mutation [13]. We also observed a great
variability among nevi: 4 of them had a high mutational load (>35%), 2 had intermediate (5–
10%) and 4 had very low mutational load (<2%) or the mutation was not present. Our results
show that nevi can also be heterogeneous regarding BRAF V600E mutational load, in contrast
with the assumption of a clonal origin of BRAF V600E mutation in melanocytic nevi proposed
by Yeh et al. [1], and in accordance with the polyclonal nature proposed by Lin et al. [14].
In order to provide more information about the reproducibility of our method, we per-
formed a replication of 17 samples. We isolated DNA from the same biopsies, but from differ-
ent tissue slides of the paraffined block. The results showed a good correlation with the
previous experiment, with a Pearson’s r of 0.96 (p<0.01).
Taking all the above into account, we compared the V600E mutational load among differ-
ent melanoma stages. We observed that most biopsies of early stages (0, IA, IB) have high
mutational load of BRAF V600E, while in most late stages (II, III, IV) biopsies the mutational
load is lower. Setting a threshold on 5% for the V600E mutational load, a significant difference
was observed between early and late stages (Fisher’s exact test, one-tailed: p = 0.00487).
Among the samples analyzed, 3 were "in situ" melanomas (Table 1). Because in situ melano-
mas rarely progress into metastasis; and at the same time, nevi can be also misclassified as in
situ melanomas, we removed these 3 samples and repeated the analysis. In this case, group
Fig 1. Immunohistochemistry (IHC) and digital PCR (dPCR) results from 3 samples. A-C) Immunohistochemical
staining of sections of paraffin-embedded biopsies for BRAF V600E (VE1 antibody) contrasted with hematoxylin-
eosin staining. D-H) dPCR results for BRAF V600E mutation. D-F) for c.1799T>A mutation and G-H)
c.1799_1800TG>AA mutation. Every dot represents a well in the chip: In blue, wells containing BRAF V600E alleles;
in red wells containing wild-type BRAF; in green, wells containing both V600E and wild-type forms, and in yellow,
wells with no DNA molecules. Sample 1: IHC: V600E BRAF positive and dPCR: high mutational load for c.1799T>A.
Sample 2: IHC: V600E BRAF negative. dPCR: negative for c.1799T>A and low mutational load for
c.1799_1800TG>AA mutation. Sample 3: IHC: V600E BRAF positive. dPCR: Really low mutational load for
c.1799T>A, but high for c.1799_1800TG>AA mutation.
https://doi.org/10.1371/journal.pone.0230136.g001
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differences were further increased (Fisher’s exact test, one-tailed: p = 0.00247). Mann-Whitney
U-test also showed that there was a significant difference between early and late stages
(p = 0.025). Altogether, these results suggest that there is an inverse correlation for BRAF
V600E mutational load and melanoma progression.
Next, we focused on stage II biopsies, due to the abundance of samples in our study and the
great variability of this stage regarding evolution to metastasis. While in general few patients
with in situ and stage I melanomas develop metastasis, many stage II patients do develop
metastasis. Among our patients with stage II melanomas (n = 38), more than a half (n = 21)
developed metastasis. Consequently, we wondered if the mutational load of BRAF V600E
could help in the prognosis of stage II patients.
Comparison of the mutational load of biopsies from stage II patients who developed metas-
tasis after surgery for primary tumors, with that from patients who remained disease-free,
showed that there is a statistically significant inverse correlation between BRAF V600E muta-
tional load and melanoma metastasis risk in stage II biopsies (Mann–Whitney U-test:
p = 0.018). We also compared both groups (metastatic and non-metastatic) vs percentage of
BRAF V600E (threshold of 5%) by means of Fisher’s exact test, and also observed a significant
difference between the classes (Fisher’s exact test, one-tailed: p = 0.013) (Table 2). To further
analyze the relevance of this observation, we performed a simple predictive modelling based
on logistic regression [15]. First, we balanced the two groups with regard to sex (p-value after
two-sample t-test of p = 0.19) and age (p-value after two-sample t-test of p = 0.136). The size of
the two balanced groups changed to n = 20 for the metastatic group and n = 16 for the non-
metastatic one. The initial mean prediction capacity of the model was 0.65 (SD = 0.077).
Prompted by this initial result, we decided to perform a more sophisticated machine learning
approach. A power analysis, varying the effect size as a parameter, showed that for a power of
80% the corresponding effect size is: 0.97 which is really close to observed effect size in our
classification (Cohen effect size measure based on mean differences, metastatic samples vs
non-metastatic sample, = 0.95). Therefore, our sample size would be equivalent to that one in
other studies requiring 80% of prediction power with the observed effect size. Given our sam-
ple size, one might wonder whether it is sufficient to correctly observe any effect while keeping
the Type II error under control. This is usually accomplished at a certain significance level by
running a power analysis, where a priori the expected effect size must be known. Here, and
given the lack of previous studies reporting BRAF differences between Metastatic and Disease
Free group conditions, we used our observed difference in the means between both groups as
an estimation of the population effect size. At the standard 5% significance level, this assump-
tion provides a decent power of approximately 80% in our dataset.
Therefore we performed a machine learning approach using a pruned Decision Tree classi-
fier, implemented in (’scikit-learn’ [16]), to predict the metastatic response (see Material and
Methods). After performing ‘Leave-One-Out’ cross-validation, the classification accuracy was
measured using different metrics, such as accuracy = 0.75, precision = 0.72 and recall = 0.9.
The cut-off value of the classifier is 33.05, which means that patients with a mutational load of
BRAF V600E lower than 33.05% are classified as “bad prognosis” and those with a value higher
than 33.05% are classified as “good prognosis”. The difference can also be visualized in a
Kaplan-Meier curve (S2 Fig).
Table 2. Mutational load comparison between stage II patients groups.
Mutational load of BRAF V600E (%)
Prognosis <5% >5%
Metastasis 18 3
Disease-free 8 9
https://doi.org/10.1371/journal.pone.0230136.t002
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Then, we tested if BRAF V600E load was a better predictor than the traditional Breslow
thickness value. We considered three scenarios: 1. using only the Breslow thickness as a predic-
tor variable, 2. only the variable mutational load of BRAF V600E, or 3. Combining the two.
The classification metric scores for a Decision Tree classifier were better for BRAF V600E
alone (accuracy = 0.75, precision = 0.72 and recall = 0.9) than Breslow Thickness alone (accu-
racy = 0.69, precision = 0.6 and recall = 0.8) or both variables together (accuracy = 0.72, preci-
sion = 0.69 and recall = 0.8). Therefore, adding the Breslow variable to BRAF V600E load into
the classifier did not increase performance. The best classification was achieved when BRAF
V600E load variable was the only predictor variable.
Based on our results, stage II patients with low mutational load of BRAF V600E seem to
have a higher risk of developing metastasis. Even though we are aware of the modest sample
size, as a preliminary approach, our results suggest that the BRAF V600E mutational load can
constitute a useful biomarker that is worth exploring further collectively by the melanoma
community.
BRAF V600E load has been previously analyzed in melanoma samples by dropled digital
PCR (ddPCR) in order to compare its precision with other techniques [6, 17]. With this study
we extent previous works and confirm that QuantStudio 3D Digital PCR System is able to
accurately measure V600E load. Furthermore, to our knowledge, our work is the first one ana-
lyzing the relationship between BRAF V600E load and prognosis.
These results do not attempt to constitute evidence against the treatment with BRAF V600E
inhibitors. Evidently, BRAF inhibitors selectively attack BRAF mutated cells. However, further
research about BRAF V600E mutational load could help understand its implication in the
prognosis.
Conclusions
The great variability of BRAF V600E mutational load observed in the samples analyzed, high-
lights the fact that tumor heterogeneity is a common feature in melanoma, where several sub-
clones can coexist, with different abilities and behaviors. Interestingly, our results suggest that
BRAF V600E is a promising biomarker of prognosis in AJCC stage II melanoma patients,
which may help to improve the personalized medical care and survival of melanoma patients.
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